The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

Summary

The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.

Conditions

• Cognitive Impairment
• Hypertension
• Aging

Interventions

DRUG

candesartan

orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months

DRUG

lisinopril

orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months

DRUG

hydrochlorothiazide

orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months

DRUG

nifedipine, long acting

If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments

DRUG

metoprolol, long-acting

If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg

Sponsors & Collaborators

• National Institute on Aging (NIA)

  collaborator NIH

• Hebrew SeniorLife

  collaborator OTHER

• University of Southern California

  lead OTHER

Principal Investigators

• Ihab Hajjar, MD · University of Southern California

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-01-31

Primary Completion

2011-12-31

Completion

2012-12-31

Countries

• United States

Study Locations